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Abstract
The post-exposure therapeutic efficacy of injectable peramivir against highly pathogenic avian influenza type A H5N1 was evaluated in mice
and in ferrets. Seventy to eighty percent of the H5N1-infected peramivir-treated mice, and 70% in the oseltamivir treated mice survived the 15-day
study period, as compared to 36% in control (vehicle) group. Ferrets were infected intranasally with H5N1 followed by treatment with multiple
doses of peramivir. In two of three trials, a statistically significant increase in survival over a 16–18 day period resulted from peramivir treatment,
with improved survival of 40–64% in comparison to mock-treated or untreated animals. Injected peramivir mitigates virus-induced disease,
reduces infectious virus titers in the lungs and brains and promotes survival in ferrets infected intranasally with this highly neurovirulent isolate. A
single intramuscular peramivir injection protected mice against severe disease outcomes following infection with highly pathogenic avian
influenza and multi-dose treatment was efficacious in ferrets.
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Influenza A viruses are negative-sense, single-stranded
segmented RNA viruses that belong to the virus family Ortho-
myxoviridae. This segmented genome structure allows influenza
viruses to evolve by reassortment of gene segments exchanged
between different influenza A strains, allowing highly virulent
variants to emerge in birds and swine and to cross species
barriers to infect humans (Ellis et al., 2004; Neumann and⁎ Corresponding author. Department of Pathology, University of Texas
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doi:10.1016/j.virol.2007.12.029Kawaoka, 2006; Normile, 2006; Shinya et al., 2005; Sturm-
Ramirez et al., 2004; Subbarao and Katz, 2000; Webster, et al.,
1997). Over 330 human cases of highly pathogenic avian in-
fluenza of the H5N1 subtype in Southeast Asia in the periods
1997 and 2003–2005 and in Turkey and the Middle East in
2005–2006, have been confirmed by the World Health Orga-
nization (Beigel et al., 2005; WHO, 2006b,c). Of these cases,
over 60% were fatal (WHO, 2006b). The avian H5N1 influenza
viruses that are currently circulating in Asia represent the most
immediate threat of a possible influenza pandemic (Cinatl et al.,
2007a; Lee et al., 2006; Poland, Jacobson, and Targonski, 2007).
Encephalitis, as a direct complication of human influenza
A viral infections is not very common (Boyd et al., 2006).
However, in contrast to the limited virulence of epidemic human
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highly pathogenic in humans (de Jong et al., 2005a) as well as in
various naturally and experimentally infected birds and mam-
mals, e.g., ferrets, mice, cats and other exotic animals (Kuiken
et al., 2006a,b, 2004, 2003; Rimmelzwaan et al., 2006; van Riel
et al., 2006; Zitzow et al., 2002) and have caused systemic
infections with involvement of the central nervous system
(Beigel et al., 2005; Lee et al., 2006; Lye, et al., 2007). This
highlights the prospect for continued emergence of neuroinva-
sive and/or neurovirulent avian influenza A variants that are
capable of crossing species barriers to infect humans.
Further H5N1 pathogenesis studies are warranted, due to
unique observations in cases of human infection with avian
influenza: 1) a high incidence of diarrhea (in 80% of cases),
which occurs prior to the onset of respiratory symptoms (Beigel
et al., 2005), and 2) case presentation with diarrhea in the
absence of respiratory symptoms, followed by the rapid onset of
coma. Several vaccine candidates against highly pathogenic
avian influenza A H5N1 viruses have been developed and are
currently undergoing clinical trials (WHO, 2006a). Manufactur-
ing of influenza vaccines, however, represents a substantial
limitation to the timely production of vaccine stocks for use
during the outbreak of avian influenza (Cox, 2005; Gerdil,
2003; Hampson, 2006). Currently, the only treatment options
for potential use in epidemic avian influenza are antiviral drugs
developed for seasonal human influenza viruses. Only two
classes of antiviral drugs are approved for influenza A treat-
ment, M2 inhibitors (amantadine, rimantadine) and neuramini-
dase inhibitors (NA) (oseltamivir, zanamivir) (Gubareva et al.,
2000). Oseltamivir carboxylate (Tamiflu, Roche Laboratories,
Inc.; Nutley, NJ) is currently approved for use in humans
N1 year of age for treatment of uncomplicated acute (within
2 days of the occurrence of symptoms) seasonal influenza
(FDA, 2006) and is administered orally as an inactive prodrug
(Mendel et al., 1998). Oseltamivir has been used for treatment
of human cases of avian influenza, with variable results (Beigel
et al., 2005). In addition, inhaled zanamivir is approved for
prophylaxis or treatment of seasonal influenza (Jefferson et al.,
2006).
Development and testing of alternatives to the use of oral
and/or inhaled treatments are necessary due to the limitations of
using inhaled treatments to halt an epidemic as well as due to
potential for an elevated rate of drug resistance to occur
following widespread usage of the available antivirals (Cinatl
et al., 2007b; Hurt et al., 2006). In addition, studies of the
efficacy of these approved antiviral drugs against highly
pathogenic avian influenza A H5N1 variants are limited
(Govorkova et al., 2007, 2001; Gubareva, et al., 2000; Leneva
et al., 2000; Yen et al., 2005) and further dosing schedules to
optimize these treatment regimens in animal models of H5N1
are necessary to provide treatment guidelines for clinicians and
to present appropriate drug supply recommendations to public
health and government officials. Inbred mice (female BALB/c
strain) and outbred ferrets (Mustela putorius furo) represent
widely accepted animal models for the study of influenza A.
Studies of oseltamivir treatment of six-week-old female mice
infected intranasally with 5 times the mouse fifty-percent lethaldose of influenza A H5N1 (A/Vietnam/1203/04), indicate that
an eight day course of treatment, but not a five day course,
protected mice from lethal disease (Yen et al., 2005). Several
studies suggest that the influenza A H5N1 isolate from a fatal
human case in 2004 (A/Vietnam/1203/04) may be more virulent
than certain 1997 Hong Kong isolates and that rapid infection of
and replication in the central nervous system may account for
this difference (Bright et al., 2003; Dybing et al., 2000; Gao
et al., 1999; Katz et al., 2000; Leneva et al., 2000; Maines et al.,
2005; Rowe et al., 2003; Zitzow et al., 2002). Due to the highly
virulent, rapid systemic dissemination of highly pathogenic
H5N1 avian influenza, particularly CNS involvement, an
injectable neuraminidase inhibitor may provide a more efficient
means of inhibiting the primary replication and multi-organ
spread of the highly lethal influenza virus, thereby alleviating
illness and ultimately promoting survival.
Peramivir (BCX-1812) is a cyclopentane analogue that is
structurally different from zanamivir and oseltamivir, and is a
potent and selective inhibitor of influenza NA (Barnard, 2000).
Previously, it was demonstrated that orally-administered
peramivir is active against various influenza A and B viruses,
including H5N1 viruses, in vitro, in vivo (Babu et al., 2000;
Bantia et al., 2001; Drusano et al., 2001; Govorkova et al.,
2001; Sidwell et al., 2001; Smee et al., 2001; Hurt et al., 2004)
and in human challenge experiments. (Barroso et al., 2005). In
order to overcome limited bioavailability, parenteral formula-
tions of peramivir are currently under preclinical and clinical
investigation. Recent studies demonstrate that a single i.m.
injection of peramivir (10 mg/kg) fully protects against lethal
outcome, and is equivalent to five days oral oseltamivir therapy
in the influenza A/H1N1 mouse model (Bantia et al., 2006).
At present, no published information about the efficacy of
injectable peramivir against highly pathogenic avian influenza
A H5N1 is available. Thus, we investigated the therapeutic
efficacy of a modified dosing schedule of peramivir delivered
by i.m. injection in influenza A/Vietnam/1203/04 (H5N1)-
infected mice and ferrets. This isolate was shown to be highly
virulent in experimental infection of BALB/c mice and in
3–5 month-old ferrets (Govorkova et al., 2005; Maines et al.,
2005) and can cause lethal infection in both animal species
without prior adaptation. Herein, we describe the pathogenesis
of this H5N1 strain in mice and ferrets, and the effects of
peramivir treatment on survival and mitigation of disease.
Results
Post-exposure therapeutic efficacy of intramuscular peramivir
against influenza A H5N1 (A/Vietnam/1203/04) in the mouse
model
Pharmacokinetic analysis indicated that the parenteral for-
mulation of peramivir was rapidly introduced into the circulation
of these mice following intramuscular inoculation (Fig. 1A). In
addition, peramivir was effective in inhibiting the NA activity of
influenza A/Vietnam/1203/04 in vitro (Hurt et al., 2006). In six-
week-old mice, we evaluated survival and disease development
following i.n. infection with H5N1 (1×10− 1–1×103 TCID50 per
Fig. 1. Effects of post-exposure peramivir treatment on survival and disease development in mice infected with influenza AH5N1. A) Pharmacokinetic (PK) analysis of
peramivir in mice.Mice (3 per group) received a single i.m. injection of 10 mg/kg of peramivir. 20 mg/kg and 30 mg/kg doses were modeled using WinNonlin® 5.0.1.
Values are presented as log/linear plot. B–D) Post-exposure efficacy of peramivir in ten-week-old mice. All mice were infected intranasally with a dose of 6×102
TCID50 of influenza A H5N1 (A/Vietnam/1203/04). Mice (10–11 per group, N) were treated via intramuscular (i.m.) injection with single (+1 h) dose (30 mg/kg) or
multiple (+1 h, daily on day +1 through day +4) doses of peramivir (30 mg/kg) or with control (vehicle, +1 h, daily on day +1 through day +4). For comparison, mice
were treated with oseltamivir (10 mg/kg/day) per os (p.o., +1 h, daily on day +1 through day +4). Animals were monitored daily for a period of 15 days for disease and
death. B) Survival curves. C–D) Severe disease development in post-exposure efficacy trial in ten week-old-mice. C) The percentage of mice in each group that
developed paralysis by day 15 is shown. D) The percentage change in body mass from day 1 was calculated for each indicated day (data shown in Supplemental Fig. 1).
Severe disease was defined as the loss of ≥20% of their initial body mass.
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treatment was subsequently evaluated by measurement of sur-
vival (Fig. 1B), disease severity (Fig. 1C and D), body temper-
ature (Suppl. Fig. 1A), and body weight (Suppl. Fig. 1B) of 10-
week-old mice infected with influenza A H5N1 (A/Vietnam/
1203/04) virus via intranasal (i.n.) route. For this peramivir ef-
ficacy study in mice, we selected a dose that killed 75% of the
mice in our H5N1 dose-response studies (data not shown), which
was equivalent to 6×102 TCID50 based on back-titration of the
inoculum. At the end of the 15 day study period, animal survival
was 70–80% in the groups receiving either a single or multiple
doses of peramivir, and 70% in the oseltamivir treatment group, as
compared to 36% in control (vehicle) group (Fig. 1B). The dif-
ference in median survival between peramivir or oseltamivir
treatment and control groups was not statistically significant.
Peramivir treatment marginally reduced the frequency of para-
lysis (Fig. 1C). The encephalitis rate was 20% (2 of 11) for the
single dose peramivir group and 30% (3 of 11) for the multipledose peramivir group in comparison to 27% (3 of 11) in the
control, but was even higher for the oral oseltamivir treated mice
(50%, 5 of 10). However, the disease onset occurred later for the
peramivir-treated mice, at 11 dpi vs. 8 dpi (Suppl. Fig. 1C). An
interesting finding was that H5N1-infection resulted in death of
mice in the absence of apparent disease symptoms and this oc-
curred with a lower frequency among peramivir-treated mice in
either single or multi-dose groups (10%, 1/10) compared to the
untreated control group (36%, 4/11) and did not occur in the
oseltamivir group. Body weight loss 1–2 days prior to death of
these mice was similar for the control (21–23% of baseline) and
the single dose peramivir treatment groups, but was not as pro-
nounced (loss of 15%) for the multiple dose peramivir group
(Suppl. Fig. 1C).
Body weight trends, including detailed body weights for
individual animals, as well as summary data by treatment
groups, are presented in Suppl. Fig. 1. To facilitate comparison
of the disease development in H5N1-infected mice with
Fig. 3. Pharmacokinetic (PK) analysis in ferrets. Ferrets (3 per group) received a
single i.m. injection of 1, 3 or 9 mg/kg of peramivir. Blood samples were
collected at the indicated pre- and post-inoculation time points and analyzed via
liquid chromatography with tandem mass spectrophotometry (LS/MS/MS). The
average log/linear plasma concentration is shown.
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loss as severe disease, which we define as the loss of ≥20% of
their initial body mass (Fig. 1D). In prior reports of influenza
drug efficacy, animals were euthanized when loss of N25% of
their original body weight was recorded (Bright et al., 2003;
Dybing et al., 2000; Gao et al., 1999; Katz et al., 2000; Leneva
et al., 2000; Maines et al., 2005; Rowe et al., 2003; Zitzow et al.,
2002). We evaluated the effect of peramivir treatment on disease
outcome, with severe disease similarly defined as≥20% loss of
body weight. Severe disease over the 15 day monitoring period
was significantly reduced in the treatment groups, as compared
to the control group (logrank test; p=0.0006). Although further
studies in this mouse model are required to demonstrate a
statistically significant effect on mortality, either a single or
multiple doses of parenteral peramivir improved the outcome of
infection with highly pathogenic avian influenza.Fig. 2. Dose-dependent survival and disease development in ferrets infected with
influenza A H5N1. Six- to eight-week-old ferrets (4–7 per group, N) were
infected intranasally with influenza A H5N1 (A/Vietnam/1203/04) using a dose
of 1.89×104 (N=7), 1.89×103 (N=7), or 1.89×102 (N=4) TCID50 per animal or
as control, with uninfected egg stock (N=2, indicated by dash). Following
infection, animals were monitored daily for a period of 16 days following
infection for death (A) and disease development (B). Animals that developed
paralysis were euthanized. The percentage of animals that developed paralysis or
encephalitis by the end of the study (day 16), calculated for each group, is
presented in B.Pathogenesis of avian influenza AH5N1 virus (A/Vietnam/1203/
04) in ferrets
Initial fifty-percent lethal dose (LD50) studies were per-
formed using virus grown in cell culture. Intranasal inoculation
resulted in dose-dependent lethality and severity of the disease
(LD50 between 1×10
2 and 1×103 TCID50), with signs of
encephalitic disease occurring between day 4 and 10 (data not
shown). This provided the basis for dose selection for the first
peramivir trial in ferrets (trial 1, detailed below). To achieve a
higher titer stock for use in the antiviral trials, the virus was
grown in eggs, sequence confirmed (Suppl. Virus Sequencing)
and the lethality confirmed by a repeat LD50 study (Fig. 2). In
this LD50 study, however, ferrets were euthanized upon
development of incapacitating disease, e.g., paralysis. Fifty-
seven percent of ferrets infected with a dose of 1.89×102 or
1.89×104 TCID50 developed paralysis by day 10; of ferrets that
received the lowest dose (1.89×102 TCID50), 100% developed
paralysis by day 10. The latter stock was utilized for subsequent
peramivir trials (trial 2 and 3, detailed below), and a higher
dosage was used for these ferret infections.
Post-exposure therapeutic efficacy of intramuscular peramivir
against influenza AH5N1 (A/Vietnam/1203/04) in the ferretmodel
The post-exposure therapeutic efficacy of peramivir was also
evaluated in outbred animals (ferrets), as pharmacokinetic
analysis of peramivir in ferrets showed rapid uptake into the
circulation following i.m. inoculation (Fig. 3). For the peramivir
efficacy studies in ferrets, we selected a dose at which N75% of
the ferrets died or developed paralysis, equivalent to N1×103
TCID50 based on back-titration of the inoculum. Pre-inocula-
tion hemagglutination inhibition test (data not shown) and
hematological analysis (white blood cell count, WBC, data
not shown) indicated that these ferrets were not naturally in-
fected with a circulating strain of influenza and that the animals
did not have any abnormal hematological changes prior to
infection.
Fig. 4. Effects of post-exposure peramivir treatment on survival in six- to eight-week-old ferrets infectedwith influenzaAH5N1.Survival curves are shown for animals tested in three
independent post-exposure efficacy trials: A) trial 1, B) trial 2, and C) trial 3. All ferrets were infected intranasally with influenza AH5N1 (A/Vietnam/1203/04) using the challenge
dose indicated in the figure legend. Prior to infection, blood was drawn for hematological evaluation. One group of ferrets was treated with multiple doses of peramivir (30mg/kg).
As controls, one group of ferrets either was treated with vehicle (drug diluent) at +1 h post-infection, and daily on day +1 through day +4 post-infection (trial 1 and trial 3) or was
untreated (trial 2). Following H5N1 infection, animals were monitored daily for a period of 16–18 days for death and disease development (see Fig. 5). Logrank test comparing the
survival for peramivir-treated and control groups was performed and the p-value is reported. D) The median survival time for the three peramivir trials is summarized. Asterisk (⁎)
indicates that the p-value obtained comparing the treatment and control (vehicle-treated or untreated) group in the respective trial via logrank test was statistically significant.
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Table 1
Effects of post-exposure peramivir treatment on disease development in six- to eight-week-old ferrets infected with influenza A H5N1
Treatment
group
Number of ferrets that developed indicated symptom/total number tested (percentage)
Trial 1 Trial 2 Trial 3
Encephalitis Paralysis Encephalitis Paralysis Encephalitis Paralysis
Peramivir 1/7 (14%) 1/7 (14%) 2/8 (25%) 0/8 (0%) 5/10 (50%) 1/10 (10%)
Controla, b 1/7 (14%) 1/7 (14%) 5/9 (56%) 4/9 (44%) 7/10 (70%) 6/10 (60%)
Six- to eight-week-old ferrets were treated with multiple doses of peramivir (30 mg/kg) or, as a control, with adrug diluent (vehicle), trial 1 and 3) at +1 h, and daily on
day +1 through day +4, or were buntreated (trial 2). Ferrets were infected intranasally with 1.5×103 TCID50 (trial 1), 1.5×10
4 TCID50 (trial 2), or 1.7×10
4 TCID50
(trial 3) of influenza A H5N1 (A/Vietnam/1203/04), as described in Fig. 4. Summary of disease development is shown.
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The therapeutic efficacy of i.m. peramivir was evaluated by
measurement of survival (Fig. 4A) and disease development
(Table 1) of seven-week-old female ferrets infected with
1.5×103 TCID50 of influenza A H5N1 (A/Vietnam/1203/04)
virus via intranasal (i.n.) route prior to peramivir treatment. The
percent survival of peramivir-treated ferrets was higher than in
the control group; 86% in peramivir treatment group, as
compared to 43% in control (vehicle) group (Fig. 4A). By day 5,
disease symptoms were present and/or death occurred, with or
without paralysis/encephalitis in the control group. The
difference in survival between the peramivir and control groups
was not statistically significant. Summary disease data is shown
in Table 1. In the peramivir treatment group, one of seven ferrets
developed encephalitis and/or paralysis (Table 1) and died the
following day (data not shown). In vehicle treatment group, two
of seven ferrets developed paralysis and/or encephalitis
(Table 1) and died on the same or a subsequent day (data not
shown); two of seven ferrets died without development of
encephalitis/paralysis.
Trial 2
A second trial of post-exposure peramivir efficacy in seven-
week-old female ferrets was performed similarly to trial 1, but
using a higher H5N1 challenge dose (1.5×104 TCID50) and a
smaller number of ferrets. In this trial (Fig. 4B), there was a
statistically significant difference in the median survival time
between groups (logrank, p=0.0041). Survival was 75% for
H5N1-infected peramivir-treated animals, as compared to 11%
for untreated animals infected at the same dose (Fig. 4B).
Peramivir extended the survival time with the majority of
treated animals surviving the entire 16-day study period,
whereas the median survival time for untreated H5N1-infected
animals was 5 days. Disease development is summarized in
Table 1. In the untreated group, encephalitis onset occurred
between day 3 and 8, and in one case, persisted up to day 11
post-infection; paralysis developed either concurrently (major-
ity of ferrets) or within 3 days of encephalitis (one ferret). By the
end of the observation period of 16 days, 44% of untreated
ferrets developed paralysis (Table 1), whereas none of the
peramivir-treated animals developed paralysis. Fewer symp-
toms were observed among peramivir-treated ferrets, and only 2
of 8 ferrets (25%) developed encephalitis; encephalitis also
occurred relatively later than for the untreated group: one on day
5 and the other on day 7. For untreated ferrets, a variety ofsymptoms, e.g., ataxia, seizure, febrile and/or moribund ani-
mals, occurred between day 2 and 10 post-infection (data not
shown). In the control group, 100% of animals inoculated with
uninfected egg stock survived and no disease development was
observed (data not shown).
Trial 3
A third trial of post-exposure peramivir efficacy was
performed with seven-week-old ferrets and a similar H5N1
challenge dose to trial 2 (1.7×104 TCID50). In this trial, there
was a statistically significant difference in the median survival
time between groups (logrank, p=0.0373). Survival was 70%
for H5N1-infected peramivir-treated animals, as compared to
30% for vehicle-treated animals infected at the same dose
(Fig. 4C). Peramivir extended the survival time with the
majority of treated animals surviving the entire 18-day study
period, whereas the median survival time for vehicle-treated
H5N1-infected animals was 8 days. Disease development is
summarized in Table 1. Disease development occurred at a
lower rate for the peramivir-treated group, with 5/10 (50%) and
1/10 (10%) developing encephalitis and paralysis, respectively,
in contrast to the encephalitis and paralysis rate for vehicle-
treated controls of 7/10 (70%) and 6/10 (60%), respectively
(Table 1). Among the vehicle-treated controls, encephalitis
onset occurred between day 3 and 9; paralysis developed either
concurrently or within 2–5 days of encephalitis (data not
shown). For the peramivir treatment group, the peak percent-
age of encephalitic animals was 30% on day 7 whereas for
the vehicle-treated group, the peak percentage was 40% on day
4–5; for the peramivir-treated group, the peak percentage of
paralyzed animals was 10% on day 10, whereas the peak for the
vehicle-treated group was 30% on day 5 (data not shown).
We evaluated the level of infectious virus at 4 and 6 days
following H5N1-infection in the lungs, brain and nasal washes
of peramivir- and vehicle-treated ferrets, which were randomly
pre-selected (N=5/group, Fig. 5). In nasal washes, the rate of
virus detection among peramivir-treated ferrets was identical to
that of the vehicle-treated control group: 100% negative (5/5) on
day 4 and 80% negative (4/5) on day 6; however, for the
vehicle-treated ferret, the titer was 75-fold higher (1×105
TCID50/g) in comparison to the peramivir-treated ferret
(1.3×103 TCID50/g). For peramivir-treated ferrets, virus was
undetectable in lung or brain on either day 4 or day 6 post-
infection (5/5, 100% negative). In contrast, the average titer for
the vehicle-treated ferret brains on day 4 and 6 was 2.6×106 and
Fig. 5. Effects of post-exposure peramivir treatment on levels of infectious virus in the lungs, brain and nasal washes in six- to eight-week-old ferrets infected with
influenza AH5N1. Ferrets were infected intranasally with influenza AH5N1 (A/Vietnam/1203/04) using the challenge dose and peramivir treatment regimen described
for Trial 3 in Fig. 4. Randomly pre-selected ferrets were euthanized at day 4 and day 6 post-infection (N=5/group at each time point). In addition, ferrets that developed
paralysis or those that survived to the end of the study (day 18) were euthanized. Organs from euthanized animals were harvested for viral titration using TCID50 assay.
The limit of detection, indicated by a dashed line, was 1×104 gram (g) of tissue for lungs/brain and 1×103 TCID50 per ml for nasal washes.
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ferrets, on day 4, 40% (2/5) of the mock-treated ferrets tested
positive and on day 6, 20% (1/5) tested positive. For vehicle-
treated ferrets, 60% (3/5) of the lungs were positive on day 6
and the average lung titer was 2.5×104 TCID50/g. These results
indicate that the virus spread systemically from the initial site of
inoculation (nasal cavity) and virus was not as frequently
detected in the lungs or brain of peramivir-treated ferrets. Of the
six ferrets that developed paralysis during the study (Table 1),
four developed paralysis by day 5–6; the two others were
paralyzed on day 8–9. The former were euthanized at the time
of death and the organ titers evaluated. For these vehicle-treated
ferrets, the average titers for brains, lungs and nasal washes
were 4.2×109 TCID50/g, 2.9×10
7 TCID50/g and 3.2×10
3
TCID50/ml, respectively. In contrast, virus was undetectable in
the lungs, brains or nasal washes of any of the ferrets that
survived to day 18 post-infection.
Discussion
Recent outbreaks of highly pathogenic avian influenza A
viruses and their high lethality in infected humans have re-
emphasized the importance of effective antiviral drugs for the
protection of human population in the case of a pandemic
(Beigel et al., 2005). Multiple approaches are ongoing to
develop antiviral drugs and vaccines against H5N1 viruses
(Stephenson et al., 2004). At the time of our studies, no
preclinical or clinical trial had yet been published demonstrating
efficacy against A/Vietnam/1203/04 isolate, one of the most
virulent human isolates. Recently, oral oseltamivir has been
shown to be efficacious against this isolate (Govorkova et al.,
2007). In this study presented here, we have evaluated the post-
exposure therapeutic efficacy of injectable peramivir, which is
an effective NA inhibitor in vitro, against the human H5N1
isolate (A/Vietnam/1203/04) in mice and ferrets. We present
encouraging data in two animal models; in ferrets, two of threeindependent trials of i.m. peramivir treatment resulted in a
significant improvement of 40–63% in survival following
H5N1-infection. Surprisingly, shedding of virus in the nasal
washes of the ferrets was low overall in this study, in
comparison to published data (Govorkova et al., 2007). This
may be explained by several factors that differ in our study from
this prior publication: 1) the lower dose of virus inoculum used,
2) the younger age of ferrets, 3) our use of the TCID50 assay,
which is not directly comparable to their EID50 titration assay
and is likely to represent a less sensitive means of titrating virus.
Mice are naturally resistant to most seasonal human influenza
Aviruses unless the virus is adapted, which can be accomplished
by serial passaging of the virus in the target animal species
(Sidwell and Smee, 2000). In contrast to human influenza A
viruses, highly pathogenic avian influenza A viruses (H5N1)
cause severe disease in adult mice (four- to eighteen-weeks-old)
without prior adaptation, characterized by loss of body weight,
hypothermia, hyperventilation and encephalitis that results in
paralysis in some animals (Maines et al., 2005). Some of the
recent isolates from Vietnam, such as the virus that was used in
this study, are highly neuroinvasive and neurotropic in mice and
grow to high titers in brains of infected mice, frequently causing
lethal encephalitis. Previous mouse studies of H5N1 infection
demonstrated that both the loss of body weight and the
development of hypothermia correlated with the encephalitic
phase in the end stage of the disease (Bright et al., 2003; Dybing
et al., 2000; Gao et al., 1999; Lipatov et al., 2003; Lu et al., 1999;
Rowe et al., 2003). We have also used these symptoms in our
study to determine the severity of the disease in mice. Our results
have shown that the majority of mock-treated animals lost more
than 20% body weight while peramivir-treated mice did not. In
addition, a single injection treatment with peramivir was com-
parable to five oral treatments with oseltamivir, although re-
duced doses of oseltamivir were not tested.
The ferret model is considered to be a more appropriate
model for comparison of the pathogenesis of H5N1 in humans
205N.E. Yun et al. / Virology 374 (2008) 198–209since the receptors for attachment of H5N1 virus in the lower
respiratory tract are similar in humans and ferrets (Maher and
DeStefano, 2004; van Riel et al., 2006). Also, in contrast to
mice, ferrets develop symptoms analogous to humans, e.g.,
fever and nasal discharge as well as diarrhea and encephalitis,
upon infection with influenza A viruses (Coates et al., 1985;
Coates, et al., 1986; Maher and DeStefano, 2004). Unfortu-
nately, due to space and biosafety limitations for work per-
formed in the BSL-4 laboratory, which is mandated for studies
using the A/Vietnam/1203/04 isolate at University of Texas
Medical Branch, only limited information was captured about
the disease caused by this virus in ferrets. However, our results
compare favorably with these other published studies, which
had smaller study size of 2–4 ferrets per dose group (Govorkova
et al., 2005; Maines et al., 2005); lethality in our study varied
from 75%–100% and we have observed a spectrum of disease
symptoms.
A limited number of publications indicate that there may be
variability in the virulence of these avian influenza isolates in
ferrets (Govorkova et al., 2005; Maines et al., 2005) and mice
(Bright et al., 2003; Dybing et al., 2000; Gao et al., 1999;
Maines et al., 2005; Rowe et al., 2003) as well as in children
(Peiris, et al., 2007), with increased virulence associated with
isolates that efficiently infect the brain. In ferrets and mice, this
may partially be observed because the inoculum is delivered
intranasally under experimental conditions, which may enable
the virus to penetrate the CNS rapidly via the olfactory route.
However, if aerosol is a main source of infection for humans
while having contact with contagious birds, the lower respi-
ratory tract could potentially become the target for the initial
infection and not the nasal cavity. In that case, the virus would
potentially have to spread systemically to the brain, which may
explain the lower rate of encephalitis associated with H5N1
infections in humans.
Experiments are ongoing in our laboratory to better char-
acterize the ability of this virus to penetrate the CNS in the ferret
model and the immune response. In particular, our aim is to
bypass the nasal cavity in the infection process in order to more
accurately represent the initiation of infection in humans. These
studies we describe here indicate that once this virus infects the
ferret brain, a high titer of virus coincides with paralysis. The
encephalitic phase does not always lead to paralysis or death
and in our experiments, some animals that presented with ataxia
or local seizures (hind-limb) recovered and survived the
infection; no infectious virus could be detected in the lungs
and brains of diseased animals that survived and were eutha-
nized at the end of the study.
Parenteral peramivir is an NA inhibitor that is worthy of
further investigation, as it would offer an alternative therapy in
instances where oral treatments may be limited or unacceptable.
As observed in the pharmacokinetic studies of i.m. injections
performed in ferrets and modeled in mice (Figs. 3 and 1A,
respectively), this formulation can achieve maximum plasma
concentrations (Cmax) of up to 20,000-fold above the IC50 for
influenza A and B isolates, including currently circulating
strains of H5N1 in Southeast Asia (0.37 nM+/−0.26 nM)
including the highly pathogenic A/Vietnam/1203/04 isolateused in these studies (0.171 nM) (Hurt et al., 2006). This
strategy quickly introduces significant concentrations of
peramivir into the circulation, which may be beneficial for
treating highly pathogenic avian influenza infections that spread
systemically.
Since our results indicate that some peramivir-treated ferrets
and mice developed encephalitis, the ability of peramivir to
effectively treat influenza infections within the CNS requires
further investigation. Additional studies are needed to better
understand the circulation of peramivir in ferrets as well as its
potential to act against the virus once in the brain. In all, our
study indicates that injectable peramivir effectively reduces the
severity of the disease and/or promotes survival in ferrets and
mice infected with the highly pathogenic influenza isolate
A/Vietnam/1203/04 (H5N1). As potential exists for selection of
H5N1-variants that are resistant to the available NA inhibitor
based drugs (de Jong et al., 2005b; Le et al., 2005), including
peramivir (Abed et al., 2002; Baz, et al., 2007), we are currently
conducting studies to evaluate this question. Nonetheless,
collectively, these data suggest that injectable peramivir might
be useful for the treatment of highly pathogenic avian influenza
infections. Both intravenous and i.m. formulations of peramivir
have been evaluated recently in volunteer subjects, and
multinational Phase 2 clinical studies for both formulations
are under investigation for the treatment of acutely-ill and
hospitalized patients infected with seasonal and life-threatening
strains of influenza. Additional preclinical as well as human
trials are ongoing to further evaluate the potential of injectable
peramivir as an effective treatment for both seasonal and avian
strains of influenza.
Materials and methods
Tissue and egg culture
Madin–Darby canine kidney (MDCK) cells were obtained
from American Type Culture Collection (Manassas, VA). Cells
were maintained in minimal essential medium (MEM) with
10% fetal bovine serum with antibiotics. SPAFAS Specific
Pathogen Free premium eggs were supplied by Charles River
Laboratories (Wilmington, MA).
Viruses
Influenza A/Vietnam/1203/04 was provided by the Influenza
Laboratory at the U.S. Centers for Disease Control and
Prevention in Atlanta, Georgia. All work with this virus isolate
was approved by institutional and federal agencies (CDC/
USDA) and was performed in the Robert E. Shope Laboratory
at BSL-4 at the University of Texas Medical Branch (Galveston,
TX). Virus stock for inoculation of animals was obtained by
cultivation for 48 h in MDCK cells or by cultivation in
embryonated chicken eggs (Charles River Laboratories,
Wilmington, MA) at 37 °C for 20–36 h. Aliquots of harvested
virus were stored at −80 °C until animal infection. Viral dose
was determined, as indicated below. All infection studies were
performed using cell grown virus stock unless indicated.
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Serial ten-fold dilutions of the virus stock or of a 10% tissue
homogenate was prepared in MEMwithout serum. MDCK cells
were grown to confluency in 96-well tissue culture plates,
washed twice with 100 μl of Dulbecco's phosphate buffered
saline (DPBS), followed by inoculation of 100 μl of each virus
dilution of virus into four replicate wells, or, as negative control,
DPBS. Plates were incubated for 90 min at 37 °C, 5% CO2, after
which an additional 100 μl of MEM was added to each well.
Plates were incubated for 4 days at 37 °C, 5% CO2. HA assay
(WHO, 2002) was performed by removing 50 μl of supernatant
from each well and transferring it to a 96-well plate, followed by
addition of 50 μl per well of a 0.5% solution of horse
erythrocytes suspended in DPBS with Ca+ and Mg2+.
Erythrocytes were allowed to settle and hemagglutination was
documented for each replicate. Virus concentration of stocks for
infection was determined as TCID50 per ml. For organ titrations,
infectious virus titers were expressed as median tissue culture
infectious (TCID50) dose per gram (g) of tissue (WHO, 2002).
Animals
BALB/c mice were purchased from Harlan (Indianapolis,
Indiana). Ferrets (Mustela putorius furo), were purchased from
Marshall Farms (North Rose, New York). Animals were
housed in a specific pathogen-free environment for a minimum
of 2–7 days until treated with antiviral drugs or infected with
influenza A H5N1. Implantation of transponders for telemetric
temperature recording was carried out in ABSL-2 and in-
fection/drug treatment performed in ABSL-4. All animal
studies were approved by the Institutional Animal Care and
Use Committee at the University of Texas Medical Branch and
carried out according to NIH guidelines. Prior to infection,
blood was drawn for routine hematological and serological
testing. Screening of ferrets for potential infection with the
circulating strains of influenza was performed using hemag-
glutination inhibition (HI) assay on serum samples obtained
on day 2 and day 8 pre-infection. Prior to virus infection via
intranasal (i.n.) route, anesthesia was performed using 5%
isoflurane.
Hemagglutination inhibition (HI) test
HI antibodies to the circulating strains of influenza A were
measured by a standard method (WHO, 2002), as follows.
Antigen was prepared from allantoic fluid harvested from
influenza A/Wyoming/03/03 (H3N2)-infected 10-day old
embryonated chicken eggs (Charles River Laboratories,
Wilmington, MA) and the total HA units of the stock was
determined as described for TCID50 assay (WHO, 2002);
antigen stock was diluted to a concentration of 8 HA units of
antigen in 50 μl of DPBS. HI test was performed using antigen,
or as negative controls, antigen or DPBS alone. As a positive
control, pooled serum from ferrets infected with influenza
A/New York/55/04 (H3N2) was used. Chicken erythrocytes
stored in Alsever's solution (CBT Farms, Chestertown, MD)were washed and re-suspended at a 0.5% dilution in DPBS with
Ca+ and Mg2+. Ferret test or control serum was mixed with
Receptor Destroying Enzyme II (RDE II, serum:enzyme ratio of
1:3, Accurate Chemical and Scientific Corp., Westburg, NY)
and was incubated at 37 °C overnight. Subsequently, the sam-
ples were heat inactivated at 56 °C for 45–60 min and diluted
1:10 in DPBS with Ca+ and Mg2+. Serum samples were then
diluted 1:2 in DPBS with Ca+ and Mg2+ in a 96-well U-
bottomed plate. An equal volume of antigen was added to all
wells except for the DPBS control; the plate was then incubated
at 37 °C for 60 min. Fifty microliters of 0.5% chicken eryth-
rocytes was added to each well, and the mixture was incubated
for 15–30 min at room temperature. The HI titers of ferret serum
samples are reported as the reciprocal of the highest dilution at
which hemagglutination was inhibited.
Hematology
Ferret blood was collected in EDTA and standard hemato-
logical analysis was performed using the HEMAVET®1700,
Drew Scientific, Inc. (Oxford, CT) on whole blood specimens to
determine platelet and differential counts, in accordance with
the manufacturer's recommendation.
Telemetry
For measurement of body temperature, animals were
anesthetized and implanted subcutaneously with BMDS IPTT-
300 transponders (chips) purchased from Bio Medic Data
Systems, Inc. (BMDS, Seaford, DE), using a trocar needle
assembly. Animals were monitored for signs of infection or of
migration of transponder for two days prior to transfer of
animals into the ABSL-4 facility. Chips were scanned using a
DAS-6007 transponder reader (BMDS). Downloading of digital
temperature data was performed in accordance with the
manufacturer's protocol.
Antiviral drugs
Peramivir (BCX-1812) and oseltamivir were synthesized by
BioCryst Pharmaceuticals, Inc (Birmingham, AL), as pre-
viously described (Kim et al., 1997). Chemical structure and
purity were verified by nuclear magnetic resonance (NMR),
high performance liquid chromatography (HPLC), CHN
analysis, and infrared (IR) spectroscopy. For antiviral studies,
these antiviral drugs were diluted in sterile saline (0.9% sod-
ium chloride) and this diluent stock was used as the “vehicle”
control.
Pharmacokinetic (PK) analysis
PK data was obtained in ferrets and mice, as follows
(Covance Laboratories, Inc, Madison, WI). Male ferrets (three
per group) were injected via i.m. route with a dose of 1, 3 or
9 mg/kg peramivir (BioCryst, Birmingham, AL). Prior to
dosing (time 0) and at time intervals between 0.083 and 72 h
following dosing, blood samples of approximately 0.5 ml were
collected and analyzed via liquid chromatography with tandem
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generated based upon modeling from a 10 mg/kg i.m. dose. PK
parameters were calculated and modeling performed using
WinNonlin® 5.0.1 (Pharsight Corp., Mountain View, CA). PK
data was obtained following a single i.m. injection of ferrets
(3 per group) with doses of 1, 3 or 9 mg/kg peramivir. Animals
were monitored for peramivir concentration in plasma over a
72 h period (Covance, Princeton, NJ).
Clinical disease
H5N1 infection and antiviral treatment studies in mice and in
ferrets were performed as detailed in the sections below. Out-
comes monitored were death, and the development of ence-
phalitis or paralysis. Standardized data recording was performed
using the following definitions: encephalitis, development of
discoordination, ataxia or transient seizures with retention of the
ability to drink and feed; paralysis, hind-limb (hemiplegic) or
quadriplegic paralysis with the inability to reach the feeder or
water bottle.
Influenza A H5N1 infection in ferrets
For the H5N1 virulence study, seven-week-old ferrets were
infected intranasally with influenza A H5N1 (A/Vietnam/1203/
04) using a range of doses from 1×10− 1 to 1×103 TCID50 of
cell culture-grown virus (N=4 per group) or using a range of
doses from 1.89×102 to 1.89×104 TCID50 of egg-grown virus
per animal (N=7 per group). Following infection, animals were
monitored daily for disease development and death for a period
of 16–19 days following infection. In the latter study, animals
that developed paralysis were euthanized with an overdose of
pentobarbital delivered intraperitoneally. Daily telemetric mo-
nitoring of body temperature was performed for a period of
14 days.
Antiviral drug treatment
Mice
Ten-week-old mice (10–11 per group) were infected
intranasally with a dose of 6×102 TCID50 of influenza A
H5N1 (A/Vietnam/1203/04) grown in MDCK cells. Subse-
quently, mice were treated with peramivir (30 mg/kg) in a single
dose at 1 h post-inoculation (+1 h) or multiple doses (+1 h,
daily on day +1 through day +4) via i.m. injection. As control,
mice were treated with drug diluent (“vehicle” at +1 h, daily on
day +1 through day +4. For comparison, mice were treated
orally (per os, p.o.) with oseltamivir (10 mg/kg/day) at +1 h and
daily on day +1 through day +4. Animals were monitored daily
for a period of 15 days for death, disease development, and
body temperature. Body mass (weight) was recorded on days
indicated in figure legend. Severe disease was defined as the
loss of N20% of their initial body mass.
Ferrets
Six- to eight-week-old ferrets were infected intranasally with
1.5×103 TCID50 (trial 1), 1.5×10
4 TCID50 (trial 2), or 1.7×10
4TCID50 of influenza A H5N1 (A/Vietnam/1203/04) using virus
stock prepared in MDCK cells (trial 1) or in eggs (trial 2 and 3).
Ferrets were then treated with multiple doses of peramivir
(30 mg/kg) or, as control, were treated with vehicle at +1 h, and
daily on day +1 through day +4 (trial 1 and 3) or were untreated
(trial 2). Following infection and drug treatment, animals were
monitored daily for a period of 16–18 days following infection
for death and disease development. Daily telemetric monitoring
of body temperature was performed. For trial 3, five animals per
group were randomly pre-selected to be euthanized on day 4
and on day 6 post-infection for organ harvest and infectious
virus titration.
Statistical analysis
Statistical analysis of survival for all groups over the
indicated period as indicated in figure legends was performed
using logrank test at a significant level of αb0.05 in GraphPad®
Prism (San Diego, CA). For pairwise comparison of the survival
of treated and untreated (or mock-treated) groups Fisher's Exact
Test was performed at a significant level of αb0.05 in
GraphPad® Prism.
Infectious virus titration in organs
Organs collected at the indicated time points were sagittally
sectioned in half. One half of each brain was homogenized in
MEM containing 10% fetal bovine serum, and a 10% sus-
pension was made. The organ suspension was maintained at
−80 °C until further processing. The titer of infectious virus was
calculated using TCID50 assay.
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